Publications concerning the background information of the therapy

(by the research group of Prof. Kreutz)

  

  

1.)          Science, 1980, 210 (1253 – 1255)

Yatvin, M.B., Kreutz, W., Horwitz, B.A., Shinitzky, M.

PH-sensitive liposomes; possible clinical implications

 

2.)          Tumor Biol., 1994, 15, 304 – 310

Th. Severin, B. Müller, G. Giese, B. Uhl, B. Wolf, S. Hanschild, W. Kreutz

"pH-dependent LAK Cell Cytotoxicity",

 

3.)          Suppl. Clinic Cancer Res. 205

AACR-NCI-EORTC Intern. Conf. (1999)

Heun, J., Müller, B., Fischer, B., Etzkorn, M., Kreutz, W.

A biophysical approach to cancer treatment: Selective pH-dependent membrane poration and inhibition of energy supply by salicylates in human tumor cells.

 

4.)          Suppl. Clinic Cancer Res. 206

AACR-NCI-EORTC Intern. Conf. (1999)

Burger, A.M., Heun, J., Steidle, C., Fiebig, H.H., Frick, E., Schölmerich, J., Kreutz, W.

Activity of pH-sensitive salicylic acid derivatives against human tumors in vivo.

 

5.)          Immunology, 2000, 99, 375-384

Müller, B., Fischer, B., Kreutz, W.

An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells. 

 

6.)          Journal of Immunotherapy, 2000, 23(2), 196-207

Fischer, B., Müller, B., Fisch, P., Kreutz, W.

An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: Implication for Cancer Immunotherapy. 

 

7.)          Clinical Immunology, 2000, 96(3), 252-263

Fischer, B., Müller, B., Fischer, K.G., Bauer, N., Kreutz, W.

Acidic pH inhibits Non-MHC-restricted killer cell functions. 

 

8.)          ASCO 2012

Drevs, J., Spangenberger, H., Jenny, M., Mueller-Huebenthal, J., Kamijo, I., Kreutz, W.

Pilot study on anti-tumor efficacy of intravenously applied synergistic combinations of salicylic acids in patients with advanced solid tumors

 

9.)          ASCO 2013

              Drevs, J., D'Urso, S., Martinez, L., Mueller-Huebenthal, J., Kamijo, I., Kreutz, W.

Update on pilot study on anti-tumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS and aspirin in patients with advanced solid tumors

 

 

 

 

Patents:

The therapy methods are protected by several international patents.

 

 

 

 

Patent list

(W. Kreutz sole inventor)

                                                                                                                             

 

Issued Patents :

 

1.                         Patent-No. :         DE 197 26 871                    June 24, 1997

                            „Synergistically acting compositions for selectively combating tumor tissue"   

                           

2.                         Patent-No. :         US, 5.985.927                     Nov. 16, 1999

                            „Medicaments for selective treatment of tumor tissue"

 

3.                         Patent-No. :         US, 6.395.720 B1                May 28, 2002

                            „Synergistically acting compositions for selectively combating tumor tissue"

 

4.                         Patent-No.:           US, 6.525.038 B1                Febr. 25, 2003

                            „Synergistic compositions for the selective control of tumor tissue"

 

5.                         Patent-No.:           EP 0817 623 B1                  Nov. 12, 2003

                            „Medicaments for selective treatment of tumor tissue"                  

 

6.                         Patent-No.:           EP 1001 756 B1                  April 07, 2004

                            „Synergistic acting compositions for selectively combating tumor tissue"

                           

7.                         Patent-No.:           US, 6.727.235 B2  April 27, 2004

                            „Synergistic compositions for the selective control of tumor tissue"

  

Above patents are also filed in Canada and Japan

 

 

 

 

 

 

Contact:               Izumi Kamijo

 

                            Project Manager

                            +49-(0)151-58826418

 

                              Email: info@oncoadvance.com

 

 

 

All rights reserved. No part of this text may be reproduced and/or published in any form by print, photo print, microfilm or any other means without the previous written permission from Prof.Dr. W. Kreutz

© 2019 Prof. Dr. W. Kreutz, Krozingerstr. 3 (Am Schlossberg), 79214 Staufen, Germany